Elevance Health Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Gail Boudreaux

Amministratore delegato

US$21.9m

Compenso totale

Percentuale dello stipendio del CEO	7.3%
Mandato del CEO	7yrs
Proprietà del CEO	0.05%
Durata media del management	6.8yrs
Durata media del Consiglio di amministrazione	11.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Gail Boudreaux rispetto agli utili di Elevance Health?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	US$6b
Jun 30 2024	n/a	n/a	US$7b
Mar 31 2024	n/a	n/a	US$6b
Dec 31 2023	US$22m	US$2m	US$6b
Sep 30 2023	n/a	n/a	US$6b
Jun 30 2023	n/a	n/a	US$6b
Mar 31 2023	n/a	n/a	US$6b
Dec 31 2022	US$21m	US$2m	US$6b
Sep 30 2022	n/a	n/a	US$6b
Jun 30 2022	n/a	n/a	US$6b
Mar 31 2022	n/a	n/a	US$6b
Dec 31 2021	US$19m	US$2m	US$6b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$17m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$5b
Jun 30 2020	n/a	n/a	US$6b
Mar 31 2020	n/a	n/a	US$5b
Dec 31 2019	US$15m	US$1m	US$5b
Sep 30 2019	n/a	n/a	US$4b
Jun 30 2019	n/a	n/a	US$4b
Mar 31 2019	n/a	n/a	US$4b
Dec 31 2018	US$14m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$5b
Jun 30 2018	n/a	n/a	US$4b
Mar 31 2018	n/a	n/a	US$4b
Dec 31 2017	US$3m	US$162k	US$4b

Compensazione vs Mercato: La retribuzione totale di Gail ($USD 21.89M ) è superiore alla media delle aziende di dimensioni simili nel mercato MX ($USD 5.75M ).

Compensazione vs guadagni: La retribuzione di Gail è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Gail Boudreaux (63 yo)

7yrs

Mandato

US$21,889,039

Compensazione

Ms. Gail Koziara Boudreaux has been an Independent Director at Target Corporation since September 23, 2021. She has been President, Chief Executive Officer and Director of Elevance Health Inc. (formerly kn...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Gail Boudreaux	President	7yrs	US$21.89m	0.047% MX$ 906.9m
Mark Kaye	Executive VP & CFO	less than a year	US$12.36m	0.0017% MX$ 32.5m
Blair Todt	Executive VP and Chief Legal & Administrative Officer	4yrs	US$8.11m	0.0044% MX$ 84.9m
Peter Haytaian	Executive VP and President of Carelon & CarelonRx	10.4yrs	US$6.98m	0.0071% MX$ 135.0m
Felicia Norwood	Executive VP & President of Government Health Benefits	6.4yrs	US$6.48m	0.0098% MX$ 186.6m
Scott Anglin	SVP, Treasurer & Chief Investment Officer	6.6yrs	Nessun dato	Nessun dato
Ronald Penczek	Senior VP	9yrs	Nessun dato	0.00057% MX$ 10.9m
Stephen Tanal	Vice President of Investor Relations	no data	Nessun dato	Nessun dato
Julie Goon	Senior Vice President of Public Affairs	11yrs	Nessun dato	Nessun dato
Kyle Weber	Chief Strategy Officer & Interim Chief Marketing Officer	less than a year	Nessun dato	Nessun dato
Charles Kendrick	Executive VP & President of Commercial Health Benefits	no data	Nessun dato	0.0022% MX$ 42.3m
Scott Towers	President of Dental Business	8yrs	Nessun dato	Nessun dato

6.8yrs

Durata media

58yo

Età media

Gestione esperta: Il team dirigenziale di ELV * è esperto e expertise (durata media dell'incarico 6.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Gail Boudreaux	President	7yrs	US$21.89m	0.047% MX$ 906.9m
Ramiro Peru	Independent Director	20yrs	US$386.76k	0.0024% MX$ 45.5m
Elizabeth Tallett	Independent Chair of the Board	11.1yrs	US$597.83k	Nessun dato
Lewis Hay	Independent Director	11.3yrs	US$362.53k	Nessun dato
Bahija Jallal	Independent Director	6.8yrs	US$371.42k	Nessun dato
Ronal Clark	Independent Director	10.5yrs	US$371.42k	Nessun dato
Ryan Schneider	Independent Director	5.1yrs	US$347.28k	0.0013% MX$ 24.7m
Robert Dixon	Independent Director	13.3yrs	US$360.34k	0.0031% MX$ 59.7m
Heath Gilbert	Member of Advisory Board	11.3yrs	Nessun dato	Nessun dato
Douglas Kiefer	Member of Advisory Board	11.3yrs	Nessun dato	Nessun dato
Karin Meng	Member of Advisory Board	11.3yrs	Nessun dato	Nessun dato
Steven Richlin	Member of Advisory Board	11.3yrs	Nessun dato	Nessun dato

11.3yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di ELV * è composto da personale esperto e esperto (durata media dell'incarico 11.3 anni).

Elevance Health Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director recently sold Mex$2.8m worth of stock

Insufficient new directors

Insufficient new directors

Insider recently sold Mex$117m worth of stock

Insufficient new directors

Senior VP recently sold Mex$7.8m worth of stock

Recent updates

Third quarter dividend of US$1.63 announced

Elevance Health, Inc. (NYSE:ELV) agreed to acquire CareBridge Medical Group, P.C.

Third quarter 2024 earnings released: EPS: US$4.36 (vs US$5.48 in 3Q 2023)

Elevance Health, Inc. Declares Dividend for the Fourth Quarter of 2024, Payable on December 20, 2024

Las Mercedes Medical Centers acquired Pasteur and Wellmax Medical Centers from Elevance Health, Inc. (NYSE:ELV).

Elevance Health, Inc. to Report Q3, 2024 Results on Oct 17, 2024

Upcoming dividend of US$1.63 per share

Clayton, Dubilier & Rice and Elevance Health Announces the Introduction of Mosaic Health, a National Care Delivery Platform

Independent Director recently sold Mex$2.8m worth of stock

Second quarter dividend of US$1.63 announced

Elevance Health, Inc. Declares Dividend for the Third Quarter of 2024, Payable on September 25, 2024

Elevance Health, Inc. to Report Q2, 2024 Results on Jul 17, 2024

Insufficient new directors

Upcoming dividend of US$1.63 per share

Insufficient new directors

Insider recently sold Mex$117m worth of stock

First quarter dividend of US$1.63 announced

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2024

Insufficient new directors

Elevance Health, Inc. to Report Q1, 2024 Results on Apr 18, 2024

StanCorp Financial Group, Inc. completed the acquisition of Life & Disability business of Elevance Health, Inc.

StanCorp Financial Group, Inc. completed the acquisition of Life & Disability business of Elevance Health, Inc.

Senior VP recently sold Mex$7.8m worth of stock

Insufficient new directors

Upcoming dividend of US$1.63 per share

Full year 2023 earnings released: EPS: US$25.38 (vs US$24.56 in FY 2022)

Elevance Health, Inc., Annual General Meeting, May 15, 2024

Insufficient new directors

Elevance Health, Inc. Declares Quarterly Cash Dividend, Payable on March 22, 2024

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2024

Elevance Health, Inc. to Report Q4, 2023 Results on Jan 24, 2024

Elevance Health Addresses Healthcare’S Digital Divide by Increasing Access to High-Quality Smartphones and Health-Related Digital Services

Senior VP recently sold Mex$8.7m worth of stock

Insufficient new directors

Third quarter 2023 earnings released: EPS: US$5.48 (vs US$6.75 in 3Q 2022)

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2023

Elevance Health, Inc. to Report Q3, 2023 Results on Oct 18, 2023

Insufficient new directors

Upcoming dividend of US$1.48 per share at 1.3% yield

Insufficient new directors

Elevance Health, Inc. Announces Executive Changes

Independent Director recently sold Mex$2.5m worth of stock

Elevance Health, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$7.79 (vs US$6.87 in 2Q 2022)

Elevance Health, Inc. to Report Q2, 2023 Results on Jul 19, 2023

Upcoming dividend of US$1.48 per share at 1.3% yield

First quarter 2023 earnings released: EPS: US$8.30 (vs US$7.48 in 1Q 2022)

Insufficient new directors

Upcoming dividend of US$1.48 per share at 1.3% yield

Elevance Health, Inc., Annual General Meeting, May 10, 2023

Elevance Health Inc. (NYSE:ELV) completed the acquisition of BioPlus Specialty Pharmacy Services, LLC from CarepathRx.

Full year 2022 earnings released: EPS: US$24.82 (vs US$25.04 in FY 2021)

Elevance Health Inc. Provides Earnings Guidance for the Fiscal Year 2023

Elevance Health Inc. (NYSE:ELV) entered into a definitive agreement Louisiana Health Service and Indemnity Company.

Elevance Health Inc. to Report Q4, 2022 Results on Jan 25, 2023

Insufficient new directors

Insufficient new directors

Upcoming dividend of US$1.28 per share

Insufficient new directors

Elevance Health Inc. (NYSE:ELV) entered into an agreement to acquire BioPlus Specialty Pharmacy Services, LLC from CarepathRx.

Elevance Health, Inc. Appoints Deanna Strable-Soethout as an Independent Director, Effective November 1, 2022

Elevance Health Inc. Provides Earnings Guidance for Full Year 2022

Elevance Health Inc. to Report Q3, 2022 Results on Oct 19, 2022

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released

Elevance Health Inc. Declares Third Quarter 2022 Dividend, Payable on September 23, 2022

Elevance Health Inc. to Report Q2, 2022 Results on Jul 20, 2022